AtomVie Global Radiopharma, a radiopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced on Tuesday that it has entered into an agreement with Radiopharm Ventures (RV), a joint venture between Radiopharm Theranostics (ASX:RAD) and MD Anderson Cancer Center (MDACC).
The agreement is for the development and production of 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody. The collaboration is intended to utilise both firm's expertise to advance novel radiotherapeutic solutions in areas of high unmet medical needs.
B7-H3, an immune checkpoint molecule, is overexpressed in various tumour types and represents a highly attractive target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is connected with tumour aggressiveness and poor outcome.
This partnership integrates RAD's platform of radiotherapeutic products and AtomVie's expertise in manufacturing and distributing radiopharmaceuticals worldwide. B7-H3 is part of a broader pipeline of distinct, highly differentiated technologies developed by Radiopharm Theranostics and RV. These include peptides, small molecules and monoclonal antibodies for use in cancer, sourced from universities and institutes worldwide.
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies